A recent phase 3 trial demonstrated survival benefits and reduced adverse effects with the use of subcutaneous delivery of antibodies in patients with epidermal growth factor receptor (EGFR)–mutated advanced NSCLC (106), indicating that the subcutaneous delivery may also offer a therapeutic benefit. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.